Proceedings of the PSK Conference (대한약학회:학술대회논문집)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Drug-drug interaction with DA-125 and the other anticancer drugs

  • Park, Kyung-Jin (Research Laboratories, Dong-A Pharmaceutical Co. Ltd) ;
  • Yoon, Hea-Sun (Research Laboratories, Dong-A Pharmaceutical Co. Lt) ;
  • Jang, Ji-Myun (Research Laboratories, Dong-A Pharmaceutical Co. Lt) ;
  • Shim, Hyun-Joo (Research Laboratories, Dong-A Pharmaceutical Co. Lt) ;
  • Kim, Soon-Hoe (Research Laboratories, Dong-A Pharmaceutical Co. Lt) ;
  • Kim, Won-Bae (Research Laboratories, Dong-A Pharmaceutical Co. Ltd)
  • Published : 2003.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

DA-125, a novel anthracycline analog containing fluorine with decreased cardiotoxicity and increased antitumor activity of adriamycin (ADM), developed by Research Laboratories of Dong-A Pharmaceutical. DA-125, water soluble prodrug of M1, is a ${\beta}$-alanine derivative of M1 (FT-ADM). DA-125 was rapidly hydrolyzed to M1, and M1 was metabolized to both M2 and M3. (omitted)

Keywords